Increased nasal abundance of Staphylococcus species during and after bronchiolitis hospitalization is associated with protection against asthma development by age 6 years (Poster 3)
Monday, May 1, 2023
1:00 PM – 2:30 PM ET
Location: Convention Center: 206
Publication Number: 3380.1
Jonathan Mansbach, Boston Children's Hospital, Boston, MA, United States; Pamela N. Luna, Baylor College of Medicine, Houston, TX, United States; Kohei Hasegawa, Harvard Medical School, Boston, MA, United States; Ashley Sullivan, Massachusetts General Hospital, Boston, MA, United States; Janice A. Espinola, Massachusetts General Hospital, Boston, MA, United States; Pedro A. Piedra, Baylor College of Medicine, Houston, TX, United States; Carlos A. Camargo, MGH/Harvard, Boston, MA, United States
Presenting Author(s)
JM
Jonathan Mansbach, MD, MPH (he/him/his)
Chief, Hospital Medicine Boston Children's Hospital Boston, Massachusetts, United States
Disclosure(s):
Jonathan Mansbach, MD, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Pamela N. Luna, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Kohei Hasegawa, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Ashley Sullivan, MS, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Janice A. Espinola, MPH: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Pedro A. Piedra, MD: ADMA (Ongoing) (Products/Services: Contractor including contracted research); Ark Bioscience (Ongoing) (Products/Services: Consultant, Contractor including contracted research); Genentech (Ongoing) (Products/Services: Consultant); GSK (Ongoing) (Products/Services: Contractor including contracted research); Icosavax (Ongoing) (Products/Services: Contractor including contracted research); Mapp Biologics (Ongoing) (Products/Services: Contractor including contracted research); Meissa Vaccines (Ongoing) (Products/Services: Contractor including contracted research); Merck (Ongoing) (Products/Services: Consultant, Contractor including contracted research); Moderna (Ongoing) (Products/Services: Consultant); Novavax (Ongoing) (Products/Services: Consultant, Contractor including contracted research); Sanofi-Pasteur (Ongoing) (Products/Services: Consultant, Contractor including contracted research); Shionogi (Ongoing) (Products/Services: Consultant, Contractor including contracted research)
Carlos A. Camargo, MD, DrPH, Jr.: I do not have any relevant financial / non-financial relationships with any proprietary interests.
